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Background: Sequential stages of B-cell development is stringently coordinated by transcription factors (TFs) network that 
include B-lineage commitment TFs (Ikaros, Runx1/Cbfb, E2A, and FOXO1), B-lineage maintenance TFs (EBF1 and PAX5) 
and stage specific set of TFs (IRF4, IRF8, BCL6, BLIMP1). Deregulation of TFs expression and activity is often occurs 
in malignant B cells. The aim of this study was to evaluate TFs expression in chronic lymphocytic leukemia cells taking into con-
sideration CD150 cell surface expression. From other side we attempted to regulate TFs expression via CD150 and CD180 cell 
surface receptors. Materials and Methods: Studies were performed on normal peripheral blood B-cell subpopulations and 
chronic lymphocytic leukemia (CLL) cells isolated from peripheral blood of 67 primary untreated patients with CLL. Evaluation 
of TFs expression was performed on mRNA level using qRT-PCR and on protein level by western blot analysis. Results: Median 
of PAX5 and EBF1 mRNA expression was higher in cell surface CD150 positive (csCD150+) compared to csCD150- CLL cases 
or normal CD19+ and CD19+CD5+ B-cell subsets. Differences in mRNA expression of IRF8, IRF4 and BLIMP1 between studied 
groups of CLL and normal B cells were not revealed. All CLL cases were characterized by downregulated expression of PU.1 and 
BCL6 mRNAs in comparison to normal B cells. At the same time elevated SPIB mRNA expression level was restricted to CLL 
cells. Protein expression of IRF4, IRF8 and BCL6 was uniformly distributed between csCD150- and csCD150+ CLL cases. 
PU.1 protein and CD20 that is direct PU.1 target gene positively correlated with CD150 cell surface expression on CLL cells. 
Ligation of CD150 and CD180 alone or in combination upregulated IRF8 and PU.1 while downregulated the IRF4 mRNA ex-
pression. Signaling via CD150 or CD180 alone elevated the level of BCL6 mRNA. Strong downregulation of IRF4 mRNA was 
observed after CD150, CD180 or CD150 and CD180 coligation on CLL cells. We found that in CLL cells CD150 is a negative 
regulator of SPIB while CD180 is involved in upregulation of EBF1 expression level. Moreover, CD180 ligation on CLL cells 
caused increase of CD150 mRNA level that is a one of the EBF1 target genes. Conclusions: Analysis of TFs expression profile 
revealed upregulated SPIB mRNA level and downregulated PU.1 in CLL cells. CD150 and CD180 receptors may modulate 
transcriptional program in CLL cells by regulating the TFs expression levels.
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Multistep B-cell development is stringently co-
ordinated by numerous input signals from the cell 
surface receptors that lead to activation of unique 
transcriptional programs [1]. Exclusive gene expres-
sion profile is determined by interplay of specific 
transcriptional factors (TFs) at the every stage of B-cell 
development started from B-lineage diversification 
until terminally differentiated plasma cells [2, 3]. Co-
operation of E2A, EBF1, PAX5 and LEF1 TFs moves 
common lymphoid progenitors to pro-B cell; tandem 
of IRF4 and IRF8 regulates pre-B cell stage; pheno-
type of transitional B cells is maintained by OBF1 and 
NF-κB; expression of BCL6, PAX5 and MITF is essential 
for germinal centre development and finally plasma 
cell differentiation is regulated by IRF4, BLIMP1, and 
XBP1 [2–4]. TFs often create mutual suppression 
loops that regulate alternative differentiation of B-cell 
subsets [2]. The block of malignant B cell maturation, 
as a rule, occurs at different stages of differentiation 
that bear phenotypic characteristic including TFs pro-
file of corresponding normal B-cell counterparts [1]. 
However, TFs expression and functions are often 
dysregulated in B-cell derived leukaemia and lym-
phoma. For example, in approximately 30% of diffuse 
large B-cell lymphoma (DLBCL) and 15% of follicular 
lymphoma (FL) genetic alteration of BCL6 gene leads 
to BCL6 constitutive expression and activation [4]. 
Overexpression of IRF4 was observed in multiple my-
eloma and activated B-cell like (ABC) DLBCL [5, 6]. 
However, it was shown that cooperation of PU.1 with 
IRF4 and IRF8 prevents pre-B acute lymphoblastic 
leukemia development [7]. Thus, IRF4 may act both 
as oncogene and tumor suppressor [8]. The block 
of terminal differentiation of malignant B cells in ABC 
DLBCL is linked to downregulation of BLIMP1 expres-
sion [1]. That is why finding new approaches that could 
modify stability, expression and activity of dysregulated 
TFs is a perspective direction for optimising treatment 
of B-cell malignancies.
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The present study is focused on evaluation 
of expression levels of key B-cell regulatory TFs 
in chronic lymphocytic leukemia (CLL) cells com-
pared to their normal counterparts. Previously, 
we showed that cell surface receptors CD150 and 
CD180 are involved in activation of pro-survival Akt 
and MAPK signaling pathways in CLL cells. How-
ever, stimulation of both receptors on CLL cells led 
to strong inhibition of Akt-mTOR, p38MAPK and JNK 
pathways [9]. Since, many of TFs are downstream 
targets of Akt and MAPK pathways we also tested 
a hypothesis whether it is possible to regulate TFs 
expression via CD150 and CD180 cell surface recep-
tors in CLL cells.
MATERIALS AND METHODS
Isolation of normal B-cell subsets and ma-
lignant CLL cells. Population of CD19+ B cells and 
CD19+CD5+ B-cell subpopulation were enriched 
from T-cell depleted peripheral blood mononuclear 
cells (PBMCs) of healthy individuals by magnetic 
separation using Dynabeads coated with sheep anti-
mouse IgG (Dynal Biotech ASA, Norway) according 
to manufacturer’s protocols. Mouse anti-CD5 (10.2) 
and anti-CD19 (HD37) mAbs were kindly provided 
by Prof. Edward A. Clark (University of Washington, 
Seattle, WA, USA). Peripheral blood of four healthy 
individuals was obtained from the Blood Transfusion 
Centre (Kyiv, Ukraine). PBMCs of previously untreated 
67 CLL patients were obtained from the Department 
of Oncohematology of R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology 
of National Academy of Sciences of Ukraine (IEPOR 
NASU), Kyiv, Ukraine. All patients were thoroughly 
informed about the study that was approved by the 
Committee on Bioethics at IEPOR.
Flow cytometry. PBMCs of all CLL patients were 
immunophenotyped on the subject of CD150 and 
CD180 expression as well as common B cell mark-
ers (CD19, CD20, CD22, CD37, CD38, CD40, CD48, 
CD95) and CLL marker (CD5, CD23, CD43). Detailed 
description of immunophenotyping procedure and im-
munophenotyping results were published earlier [9]. 
PBMCs from CLL patients were used for in vitro 
stimulation assay only when the level of CD19+ cells 
was more than 95% and these cells coexpressed 
CD150 and CD180 receptors.
In vitro cell stimulation. To initiate signaling via 
CD150 and CD180 receptors 10•106 of CD150+CD180+ 
PBMCs from CLL patients were incubated with 
anti-CD150 (IPO3, IEPOR NASU) or/and anti-
CD180 (G28-8, kindly provided by Prof. Edward Clark, 
University of Washington, Seattle, WA, USA) mAbs both 
at final concentration 10 µg/ml in RPMI-1640 medium 
supplemented with 10% FCS. In experiments with 
CD150 mRNA upregulation CD150-CD180+ PBMCs 
from CLL patients were used. PBMCs cultivated in me-
dium alone were used as a negative control. Stimula-
tion was stopped after 4 h of incubation with ice cold 
PBS + 0.01% NaN3.
Western blot analysis. Cell lysis, gel electro-
phoresis, western blot analysis were performed 
as described early [10]. The list of followed anti-
bodies was used for western blot analysis: goat 
anti-IRF4, anti-IRF8, anti-Actin, anti-BLIMP1, rabbit 
anti-BCL6 (all from Santa Cruz Biotechnology, USA), 
rabbit anti-PU.1 (Cell Signaling Technology, Beverly, 
MA, USA). Secondary goat anti-rabbit and donkey 
anti-goat HRP-conjugated antibodies were from 
Santa Cruz Biotechnology (USA). Clarity Western 
ECL substrate (Immunо-Star HRP, BioRad, USA) 
and medical X-ray film (AGFA, Belgium) were used 
for visualization.
Quantitative RT-PCR. A detailed description of to-
tal RNA isolation, cDNA synthesis and real-time PCR 
were reported elsewhere [10]. The following forward 
(For) and reverse (Rev) primers for real-time PCR were 
used: IRF4: For 5ʹ-CCACTACCTCCTTTCCTATC-3ʹ, 
Rev 5ʹ-CCGTTCCTTTTCAGAGTCCT-3ʹ; IRF8: For 
5ʹ-CCAACAGATCACCGTCTAA-3ʹ, Rev 5ʹ-AAGTG-
CAAAGTAAGGCATC-3ʹ; PU.1: For 5ʹ-CTTCCAGTTCTC-
GTCCAA-3ʹ, Rev 5ʹ-GAGCTTCTTCTTCACCTTC-3ʹ; 
SPIB: For 5ʹ-GCATACCCCACGGAGAACT-3ʹ; Rev 
5ʹ-GGCTGTCCAACGGTAAGTCT-3ʹ, BCL6: For 5ʹ-CTC-
CGTGCCCATGTGCTTA-3ʹ; Rev 5ʹ-GAGTCTGAAGGT-
GCCGGAAA-3ʹ, EBF1: For 5ʹ-GTACCATGCTGGTCTG-
GAGTG-3ʹ; Rev 5ʹ-GTGTGACTTCCACAACACCAGG-3ʹ, 
PAX5: For 5ʹ-GTCCCAGCTTCCAGTCACAG-3ʹ; Rev 
5ʹ-CGGAGACTCCTGAATACCTTCG-3ʹ. As internal 
control gene for normalization was chosen TATA-box 
binding protein (TBP): For 5ʹ-CCACTCACAGACTCT-
CACAAC-3ʹ; Rev 5ʹ-CTGCGGTACAATCCCAGAACT-3ʹ. 
The PCR cycling conditions were the following: 10 min 
at 95 °C, 40 cycles of 15 s at 95 °C and 40 s at 60 °C. The 
threshold cycle (Ct) values were determined for the 
internal control (TBP) and the tested genes at the 
same threshold level in the exponential phase of the 
PCR amplification curves. The Ct method was used 
to calculate test genes expression level normalized 
to the endogenous control (in case of TFs expression 
in CLL cells and normal B cells subsets). Experiments 
with receptors ligation were additionally normalized 
to untreated control cells. Results were presented 
in relative units or fold change. Dissociation curve 
analysis was performed after every run to check the 
specificity of the reactions. For all types of cell samples 
3–5 reactions (each in triplicates) were run for each 
genes with internal control and standard error of the 
mean (SEM) was calculated.
Statistical analysis. Obtained data were anal-
ysed by unpaired Mann — Whitney U test using Prism 
software Version 4.0. Statistical significance between 
groups was assessed as p ≤ 0.05. Pearson’s coef-
ficient was used for determination of correlation 
between variables. Box plots showed the results 
of TFs mRNA expression level where whiskers means 
maximum and minimum values, the line within the 
rectangle shows the median, and the top and bottom 
of the rectangle represent the third and first quartile, 
respectively.
Fig. 1. TFs mRNA expression levels in CLL cells (qRT-PCR). The csCD150− CLL cells (n = 6) and csCD150+ CLL cells (n = 6) were compared 
to CD19+ and CD19+CD5+ PB B cells (4 donors).*p ≤ 0.05 compared to CD19+ normal B cells. **p ≤ 0.05 compared to CD19+CD5+ normal B cells
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ous ligation of these receptors on CLL cells resulted 
in strong downregulation of IRF4 mRNA (Fig. 3, g). 
Coligation of CD150 and CD180 did not have any ad-
ditive effect on IRF4 mRNA downregulation. PU.1 and 
SPIB as the partners could act in cooperation with 
IRF4 and IRF8 TFs [16]. Stimulation of CLL cells via 
CD150 or CD180 receptors alone or their combina-
tion resulted in increased PU.1 mRNA level in CLL 
cells with additive effect of CD150 and CD180 coliga-
tion (Fig. 3, e). At the same time, CD150 ligation led 
to downregulation of SPIB mRNA level in malignant 
B cells, while CD180 and CD150 + CD180 ligation 
did not have any impact on regulation of SPIB ex-
pression level (Fig. 3, f). Taken together, CD150 and 
CD180 receptors are involved in regulation of TFs 
mRNA expression levels in CLL cells. CD150 and 
CD180 receptors alone or their combination had 
unidirectional effect on downregulation of IRF4, up-
RESULTS AND DISSCUTION
CLL cells is clonal malignant B cells that according 
to gene expression signature is closely related to CD5+ 
peripheral blood B-cell subpopulation [11]. That 
is why peripheral blood CD19+ B cells and CD19+CD5+ 
B cells obtained from healthy individuals were used 
in our study for comprehensive analysis of TFs profile 
expression between CLL cells and normal B cell coun-
terparts. The present study is focused on the TFs that 
maintain B-cell identity (EBF1 and PAX5) and regulate 
differentiation from naïve B cell stage toward plasma 
cells (IRF4, IRF8, PU.1, SPIB, BCL6, and BLIMP1). 
CLL cases were grouped according to the cell surface 
CD150 expression. We tested the hypothesis that cell 
surface CD150 positive (csCD150+) and CD150 nega-
tive (csCD150−) CLL cells may stop their maturation 
at the different stages of B-cell development and 
therefore could have diverse TFs expression profiles.
mRNA expression level of B-cell identity markers 
PAX5 and EBF1 was similar in studied normal B cell 
subsets and csCD150− CLL cases (Fig. 1, a, b). How-
ever, median of PAX5/EBF1 expression was higher 
in csCD150+ than in csCD150− CLL cases. CLL cells 
showed the similar mRNA expression levels of IRF8 and 
BCL6 regardless of csCD150 expression (Fig. 1, c, d). 
BCL6 mRNA expression was higher in normal B cells 
that in CLL cells (p ≤ 0.03) (Fig. 1, d). All tested CLL 
cases were characterised by lower level of PU.1 mRNA 
compared to normal B-cell subpopulations (p ≤ 0.02) 
(Fig. 1, e). On the other hand, the level of SPIB 
mRNA was significantly higher in csCD150− as well 
as csCD150+ CLL cells than in normal B cell subsets 
(Fig. 1, f). Expression level of IRF4 was similar in CLL 
and normal B cells (Fig. 1, g). mRNA expression level 
of BLIMP1 — master regulator of plasma cell develop-
ment, was low in all tested normal B cell subsets and 
CLL cells (Fig. 1, h). According to obtained results CLL 
cells has similar profile in mRNA expression of IRF4, 
IRF8, EBF1, and PAX5 TFs to normal peripheral blood 
B-cell subpopulations. Unique feature of malignant 
CLL cells is upregulated mRNA expression of SPIB 
and downregulated PU.1 and BCL6 TFs.
To clarify whether csCD150− and csCD150+ CLL 
cells have any differences in TFs expression on protein 
level we used western blot analysis. High expres-
sion levels of IRF4 and IRF8 proteins were detected 
in all CLL cases regardless of csCD150 expression 
(Fig. 2, a). All CLL cases were negative for BLIMP1 pro-
tein expression (data not shown). BCL6 protein was re-
vealed only in 31% of CLL cases despite the presence 
of BCL6 mRNA in all studied CLL cases. Moreover, 
BCL6 expression did not correlate with cell surface 
CD150 expression. At the same time, PU.1 protein 
was predominantly expressed in csCD150+ CLL cases 
regardless of the uniform expression of PU.1 mRNA 
in CLL (see Fig. 2, a, Fig. 1, e). Furthermore, 
PU.1 protein level positively correlated with cell sur-
face CD150 expression (r = 0.4, p < 0.05). The level 
of PU.1 protein was 14 times higher in csCD150+ than 
in csCD150− CLL cases (p = 0.002) (Fig. 2, b). It was 
shown that CD20 receptor is one of the PU.1 target 
genes [12]. We checked whether any correlations ex-
ist between cell surface CD150 and CD20 expression 
in CLL cases. Indeed we found positive correlation 
between CD150 and CD20 cell surface expression 
in CLL cases (r = 0.45, p ≤ 0.05). Median of CD20 cell 
surface expression was higher in csCD150+ CLL 
cases (Fig. 2, c) (p = 0.01). Thus, upregulated levels 
of PU.1 protein expression and its target CD20 were 
correlated with cell surface CD150 expression in CLL 
cells.
Numerous data suggest that CD150 is involved 
in activation of Akt and MAPK signaling in normal 
and malignant B cells [9, 13–15]. In case of CLL, 
CD150 could realize its signaling properties alone 
or together with CD180 receptor [9]. Since many 
of downstream targets of Akt and MAPK pathways 
are TFs, we test the hypothesis whether CD150 and/
or CD180 are involved in regulation of TFs expression 
in CLL cells. To check this we performed in vitro ligation 
of CD150 and CD180 alone or simultaneously on CLL 
cells with followed evaluation of TFs mRNA levels. 
These receptors were not involved in B-lineage main-
tenance TF PAX5 expression level regulation (Fig. 3, a). 
Only CD180 ligation on CLL cells leaded to upregula-
tion of EBF1 mRNA level and CD150 receptor did not 
abrogate this effect of EBF1 (Fig. 3, b). Expression 
level of IRF8 mRNA was significantly upregulated 
in CLL cells after ligation of any if these receptors alone 
or in combination (Fig. 3, c). CD150 or CD180 alone, 
but not CD150 and CD180 ligation upregulated 
BCL6 expression in CLL cells (Fig. 3, d). In opposite, 
crosslinking of CD150 or CD180 alone and simultane-
Fig. 2. TFs protein expression in CLL cells: a — protein expres-
sion of BCL6, IRF4, IRF8, and PU.1 in csCD150− and csCD150+ 
CLL cases. Results of western blot analysis; b — densitometry 
analysis of PU.1 expression level in csCD150- and csCD150+ 
CLL cases. Results were normalized to actin expression and 
presented in relative units; c — cell surface CD20 expression 
level in csCD150− and csCD150+ CLL cases. Flow cytometry 
analyses. Results are presented as GeoMean MFI ratio of antigen 
to isotype control. *p = 0.05 compared to csCD150− CLL cases
Fig. 3. CD150 and CD180 mediated regulation of PAX5 (a), EBF1 (b), IRF8 (c), BCL6 (d), PU.1 (e), SPIB (f), and IRF4 (g) mRNA 
expression. Results are presented as a mean of mRNA expression in three independent CD150+CD180+ CLL cases. (h) CD150 mRNA 
expression level in csCD150− CLL cells after CD180 ligation in three independent CLL cases. *p ≤ 0.05 compared to control (CLL 
cells cultivated in medium alone)
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Described here regulation of TFs expression via cell 
surface receptors is only one side of crosstalk between 
TFs and cell surface receptors. Thus, number of TFs 
such as EBF1, E2A, PU.1, IRF4, STAT6, and NF-κB 
(RELA) could bind to SLAMF1 promoter and regulate 
its activity [34]. The early B-cell factor 1 (EBF1) inter-
acts with specific binding sites both in the promoter 
and in the enhancer regions of the SLAMF1 gene and 
is a key regulator of SLAMF1 expression in human and 
mouse B cells [34, 35]. In CLL cells CD150 cell surface 
expression is significantly downregulated compared 
to normal B lymphocytes [36]. Previously it was shown 
that EBF1 protein expression was not detected in CLL 
cases both with mutated and unmutated IGHV [11]. 
In our study EBF1 mRNA level was higher in csCD150+ 
CLL cells than in csCD150− CLL cells, but whether 
EBF1 mRNA is translated in these CLL cases was not 
addressed. Absence or low level of EBF1 expression 
could result in significantly decreased cell surface 
CD150 expression level in CLL cells compared to nor-
mal periphe ral blood B cells. Our study showed that 
CD180 is specific positive regulator of EBF1 mRNA 
expression. Moreover in normal B cells CD180 is a most 
potent upregulator of CD150 expression [37]. That 
is why we tested a hypothesis whether it is possible 
to regulate CD150 expression via CD180 receptor in CLL 
cells. Indeed, ligation of CD180 on CLL cells led to more 
than two fold upregulation of CD150 mRNA expression 
(Fig. 3, h). According to results published earlier cell 
surface expression of CD150 and CD180 is positively 
correlated and these receptors coexpression is ob-
served in 59% of CLL cases. However, 11% of CLL 
cases were positive only for csCD180 expression [9]. 
Since, cell surface CD150 expression is associated 
with favourable clinical outcome of CLL patients and 
csCD150+ CLL cells are more sensitive to chemothera-
peutic drugs [36] upregulation of CD150 cell surface 
expression have a good perspectives in optimization 
of CLL treatment. Signaling via CD180 may be one of the 
possible approaches to induce CD150 cell surface ex-
pression in CD150− CLL cells that will result in modula-
tion of CLL B-cell pathobiology.
Taking together, our study showed that CLL cells 
are characterised by decreased PU.1 and elevated 
SPIB mRNA levels compared to normal B-cell coun-
terparts. Protein expression of PU.1 and its direct 
target CD20 positively correlated with cell surface 
CD150 expression in CLL cells. Ligation of CD150 and 
CD180 alone or in combination upregulated IRF8 and 
PU.1 while downregulated of IRF4 mRNA expres-
sion. Signaling via CD150 or CD180 elevated the level 
of BCL6 mRNA. We found that in CLL cells CD150 is a neg-
ative regulator of SPIB whereas CD180 is involved in up-
regulation of EBF1 expression level. Moreover, CD180-
mediated signaling leaded to increased CD150 mRNA 
level in CLL cells and could be considered as a potential 
positive regulator of CD150 expression level in malignant 
CLL cells. Thus, CD150 and CD180 receptors may modu-
late transcriptional program in CLL cells by regulating the 
TFs expression levels.
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regulation of IRF8 and PU.1 mRNA in CLL cells. Also, 
signaling via CD150 as well as CD180 increase the level 
of BCL6 mRNA expression. In addition, CD150 recep-
tor is negative regulator of SPIB mRNA expression 
while CD180 is a positive regulator of EBF1 mRNA 
in CLL cells.
CLL is a disease of CD5+CD19+CD23+ B cells, 
which are accumulated in peripheral blood, bone 
marrow and second lymphoid organs, resulting from 
disbalance between cell proliferation and apoptotic 
death [17]. Cellular origin of CLL cells is still contro-
versial. Existence of two CLL subtypes with presence 
or absence of somatic hypermutations in a variable 
region of heavy chain immunoglobulin genes (IGHV) 
indicates that malignant B cells in near half of CLL 
cases derived from germinal center (GC)-experienced 
B cells, while other half of CLL cases stoped their dif-
ferentiation at the stage of naïve B cells [11]. Based 
on the latest data CD5+CD27− peripheral blood B cells 
are the most adequate normal B cell analogue for 
CLL cells with unmutated IGHV. Rare subpopulation 
of CD5+CD27+ memory B cells could give rise for CLL 
cells that carry mutated IGHV [11]. It was revealed 
earlier that expression levels of lymphoid enhancer-
binding factor 1 (LEF1), receptor tyrosine kinase-like 
orphan receptor 1 (ROR1), fibromodulin (FMOD), 
T-cell leukemia/lymphoma 1 (TCL1), Ataxin (ATXN1), 
early B-cell factor 1 (EBF1) and p27 are significantly 
different in CLL cells compared to normal B-cell 
analogues [18]. In our study, in addition to evaluation 
of B-cell stage specific TFs mRNA expression, we re-
vealed deregulation in expression of E26-transforma-
tion specific (ETS) TFs PU.1 and SPIB in CLL cells. 
We found upregulated mRNA expression level of SPIB 
and downregulated PU.1 in CLL cells. Abundantly ex-
pressed SPIB mRNA in CLL B cells was also showed 
by Stratowa et al. [19]. SPIB is expressed in normal 
B cells starting from pre-B cells and is upregulated 
in GC B cells [20]. Similarly to PU.1, it is involved 
in BCR mediated signaling, GC formation and inhibits 
plasma cell differentiation [21, 22]. However, in con-
trast to PU.1 knockdown, deletion of SPIB gene did not 
lead to defects in B-cell development that fully abro-
gates B cell formation [23, 24]. Both PU.1 and SPIB 
could form a heterodimers with interferon regulatory 
factors — IRF4 and IRF8 [8, 16]. Nevertheless, SPIB 
is preferential partner for IRF4 [24]. SPIB is a subject 
for translocation and amplification in ABC DLBCL, 
where together with IRF4 it promotes malignant B cells 
survival via activation of NF-κB signaling and inhibiting 
of INFβ expression [6]. Highly expressed IRF4 in all 
examined CLL cases more likely interacts with SPIB 
rather than with PU.1 binding partner because ex-
pression level of PU.1 is low and heterogeneous 
in CLL cases despite the uniform high expression 
of IRF4 and SPIB (Fig. 1, f, g; Fig. 2, a). Propagation 
of CLL cells similarly to ABC DLBCL B cells is mostly 
dependent on BCR tonic signaling that is main activa-
tor of IRF4 expression [25]. So, IRF4/SPIB-mediated 
pro-survival program may also be realised in CLL cells. 
Here we showed that CD150 together with CD180 are 
negative regulators of IRF4 expression. However, only 
CD150 is involved in downregulation of SPIB (Fig. 3, f). 
So, CD150-mediated downregulation of IRF4 and SPIB 
expression could diminished their dimer formation and 
therefore inhibit transcription program orchestrated 
by IRF4/SPIB in CLL cells. The role of IRF4 in CLL 
pathogenesis is controversial. In the mouse model 
IRF4 knockout in B1 subpopulation is sufficient for 
development of CLL [26, 27]. At the same time, several 
mutations in IRF4 DNA binding domain in primary CLL 
patients are associated with better prognosis [28]. 
IRF4 function in CLL development and maintaining 
could be different and depends on signaling back-
ground and expression level of binding partner. That 
is why, the role of IRF4, SPIB and PU.1 in CLL B-cell 
pathobiology needs further investigation.
TF PU.1 is essential for generation of myeloid 
cell lineage and B-cells development [23]. In B cells 
PU.1 is a positive regulator of immunoglobulin heavy 
and light chains, CD79, CD72, and CD20 expres-
sion [23]. Downregulated PU.1 mRNA and differential 
protein expression in CLL cells compared to normal 
B-cell analogues may be linked to decreased cell 
surface IgM, CD20 and CD79 expression in CLL 
cells. Expression of PU.1 is deregulated in numerous 
of B-cell malignancies, including Hodgkin’s lympho-
mas (HL), FL, DLBCL, and multiple myeloma [29, 30]. 
Upregulation of PU.1 expression in HL and multiple 
myeloma cells lead to apoptosis of malignant B cells, 
moreover, higher PU.1 level is associated with bet-
ter clinical outcome in FL patients, lower PU.1 level 
was observed in aggressive ABC DLBCL [29–32]. 
CD38 and ZAP-70 double negative CLL cases are 
characterised by higher PU.1 mRNA expression that 
supposed to consider PU.1 expression as surrogate 
prognostic marker of favourable clinical outcome [29]. 
All these data indicate that PU.1 is functioning as a tu-
mor suppressor for malignant B cells. For the first time 
we revealed correlation between expression levels 
of PU.1 protein and cell surface CD150 in CLL cells. 
Moreover, expression level of CD20 that is a PU.1 tar-
get was also elevated in csCD150+ CLL cases. Expres-
sion level and density of CD20 on CLL cells is very im-
portant, since anti-CD20 monoclonal antibodies ritux-
imab, ofatumumab and obinutuzumab are included 
in first-line therapy of CLL [33]. As follows, the higher 
protein levels of PU.1 and CD20 in csCD150+ CLL 
cases are additional indirect evidences for association 
of CD150 expression with favourable CLL outcome. 
Moreover, we showed that CD150 alone or together 
with CD180 led to strong upregulation of PU.1 mRNA 
expression level in CLL cells (Fig. 3, e). In multiple 
myeloma cells PU.1 directly binds to IRF4 promoter 
and repress it activity [30]. So, in CLL cells PU.1 up-
regulation after CD150 or/and CD180 ligation could 
be linked to decreased level of IRF4. Further explora-
tion of CD150/CD180-PU.1-CD20 axis will reveal the 
perspectives of transcriptional program regulation 
in CLL cells via cell surface receptors.
298 Experimental Oncology 39, 291–298, 2017 (December)
18. Ghamlouch H, Darwiche W, Hodroge A, et al. Factors 
involved in CLL pathogenesis and cell survival are disrupted 
by differentiation of CLL B-cells into antibody-secreting cells. 
Oncotarget 2015; 6: 18484–503.
19. Stratowa C, Loffler G, Lichter P, et al. CDNA micro-
array gene expression analysis of B-cell chronic lymphocytic 
leukemia proposes potential new prognostic markers involved 
in lymphocyte trafficking. Int J Cancer 2001; 91: 474–80.
20. Montes-Moreno S, Ramos-Medina R, Martinez-
Lopez A, et al. SPIB, a novel immunohistochemical marker 
for human blastic plasmacytoid dendritic cell neoplasms: char-
acterization of its expression in major hematolymphoid neo-
plasms. Blood 2013; 121: 643–7.
21. Garrett-Sinha LA, Su GH, Rao S, et al. PU.1 and 
Spi-B are required for normal B cell receptor-mediated signal 
transduction. Immunity 1999; 10: 399–408.
22. Schmidlin H, Diehl SA, Nagasawa M, et al. 
Spi-B inhi bits human plasma cell differentiation by repressing 
BLIMP1 and XBP-1 expression. Blood 2008; 112: 1804–12.
23. Carotta S, Wu L, Nutt SL. Surprising new roles for 
PU.1 in the adaptive immune response. Immunol Rev 2010; 
238: 63–75.
24. Solomon LA, Li SK, Piskorz J, et al. Genome-wide 
comparison of PU.1 and Spi-B binding sites in a mouse B lym-
phoma cell line. BMC Genomics 2015; 16: 76.
25. Burger JA. B-cell receptor signaling in chronic lym-
phocytic leukemia and other B-cell malignancies. Clin Adv 
Hematol Oncol 2016; 14: 55–65.
26. Shukla V, Ma S, Hardy RR, et al. A role for IRF4 in the 
development of CLL. Blood 2013; 122: 2848–55.
27. Shukla V, Shukla A, Joshi SS, et al. Interferon regula-
tory factor 4 attenuates Notch signaling to suppress the deve-
lopment of chronic lymphocytic leukemia. Oncotarget 2016; 
7: 41081–94.
28. Havelange V, Pekarsky Y, Nakamura T, et al. 
IRF4 mutations in chronic lymphocytic leukemia. Blood 
2011; 118: 2827–9.
29. Huskova H, Korecka K, Karban J, et al. Oncogenic 
microRNA-155 and its target PU.1: an integrative gene ex-
pression study in six of the most prevalent lymphomas. Int 
J Hematol 2015; 102: 441–50.
30. Ueno N, Nishimura N, Ueno S, et al. PU.1 acts 
as tumor suppressor for myeloma cells through direct tran-
scriptional repression of IRF4. Oncogene 2017; 36: 4481–97.
31. Torlakovic EE, Bilalovic N, Golouh R, et al. Prog-
nostic significance of PU.1 in follicular lymphoma. J Pathol 
2006; 209: 352–9.
32. Yuki H, Ueno S, Tatetsu H, et al. PU.1 is a potent 
tumor suppressor in classical Hodgkin lymphoma cells. Blood 
2013; 121: 962–70.
33. Jain N,O’Brien S. Initial treatment of CLL: integrat-
ing biology and functional status. Blood 2015; 126: 463–70.
34. Schwartz AM, Putlyaeva LV, Covich M, et al. Early 
B-cell factor 1 (EBF1) is critical for transcriptional control 
of SLAMF1 gene in human B cells. Biochim Biophys Acta 
2016; 1859: 1259–68.
35. Vilagos B, Hoffmann M, Souabni A, et al. Essential 
role of EBF1 in the generation and function of distinct mature 
B cell types. J Exp Med 2012; 209: 775–92.
36. Bologna C, Buonincontri R, Serra S, et al. SLAMF1 reg-
ulation of chemotaxis and autophagy determines CLL patient 
response. J Clin Invest 2016; 126: 181–94.
Copyright © Experimental Oncology, 2017
